Delcath Systems Announces Healthcare Setting Locator For HEPZATO™ KIT (melphalan/Hepatic Delivery System) On The hepzatokit.com Website
Portfolio Pulse from Benzinga Newsdesk
Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company, announced the launch of a Healthcare Setting Locator on the hepzatokit.com website for its HEPZATO KIT, a liver-directed treatment for metastatic uveal melanoma. The Locator helps patients, caregivers, and healthcare providers find treatment locations. This follows the establishment of a permanent J-Code for HEPZATO, facilitating access to this treatment.
February 22, 2024 | 10:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Delcath Systems launches a Healthcare Setting Locator for its HEPZATO KIT, enhancing access to treatment for metastatic uveal melanoma.
The launch of the Healthcare Setting Locator for HEPZATO KIT by Delcath Systems is likely to positively impact the company's stock in the short term. This tool not only enhances the visibility and accessibility of the treatment but also demonstrates the company's commitment to supporting patients and healthcare providers. The establishment of a permanent J-Code for HEPZATO further facilitates insurance billing and access, potentially increasing the adoption and use of the treatment. These developments could lead to increased revenue and positive market perception.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100